Gastric inhibitory polypeptide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Gastric inhibitory polypeptide
Accession Number
DB15217
Type
Biotech
Groups
Investigational
Description

Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).

Synonyms
  • GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE
Categories
UNII
1O4H75S7H2
CAS number
100040-31-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when 2,4-thiazolidinedione is combined with Gastric inhibitory polypeptide.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Gastric inhibitory polypeptide.
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Gastric inhibitory polypeptide.
AcebutololThe therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Gastric inhibitory polypeptide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Gastric inhibitory polypeptide.
AgmatineThe risk or severity of hypoglycemia can be increased when Agmatine is combined with Gastric inhibitory polypeptide.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Gastric_inhibitory_polypeptide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDiabetes Mellitus (DM)1
1CompletedTreatmentType 2 Diabetes Mellitus1
1, 2CompletedBasic ScienceDiabetes Mellitus (DM)1
Not AvailableCompletedNot AvailableCystic Fibrosis (CF)1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceMaturity-Onset Diabetes of the Young, Type 31

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:01 / Updated on November 02, 2019 03:31